ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab

ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab

Source: 
Endpoints
snippet: 

Drug pricing watchdog ICER keeps its eye on what price point a drug is best suited for based on clinical benefit — and the group’s newest draft report takes a closer look at MS treatments compared to a new one awaiting the FDA’s final say.